88 Energy outperforms 3 month Nymex Oil index on the eve of drilling campaign

|

Published 22-MAR-2017 16:32 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

88 Energy (ASX:88E AIM:88E) advised the market on Wednesday that it had completed the rig mobilisation at Icewine#2 in preparation to test the HRZ shale, located onshore North Slope of Alaska.

There is a traditional hiatus over the Christmas/winter period in that region, and this often tends to lead to share price softness, however in 88E’s case it is trading broadly in line with where it was three months ago.

Of even more importance though, and perhaps indicative of positive investor sentiment regarding the upcoming drilling campaign is the group’s three month share price performance compared with the NymexOil (light sweet crude) index.

As the Commsec chart indicates below, with drilling about to commence 88E’s shares have broken above the index trend line.

Of course it should be noted here that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

88E’s Managing Director, Dave Wall said the well was on schedule to spud in April 2017 with stimulation and flow tests of the HRZ shale expected to commence in June/July.

It is worth noting that current modelling by Hartleys suggested an oil price of US$40 per barrel was a breakeven point, indicating that despite a recent decline in the oil price, the Icewine project remains very much in the money.

Broker price target implies share price upside of 100%

Gavin Van Der Wath from EverBlu Research initiated coverage of 88E in November, placing a buy recommendation on the stock with a target price of 8 cents, a 100% premium to the current share price.

He is of the view that the project provides ‘compelling prospectivity’, confirmed by the project’s maiden well, which prompted the decision to drill an appraisal well.

In summarising the merits of the Icewine project, Van Der Wath said, “We believe that a successful appraisal well, the potential resource size and subsequent scope of commercial development would attract the attention of all the oil majors, placing 88E in a strong negotiating position and allowing the company its pick of partners should it so choose.”

However, broker projections and price targets are only estimates and may not be met, so investors should seek professional financial advice for further information.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X